Search Results - (Author, Cooperation:Bunge)
-
1Printed BooksStaff View Availability
Person(s): Bunge, MarioType of Medium: UnknownPages: 341 S.Series Statement: Treatise on Basic PhilosophyLanguage: German -
2Printed BooksStaff View Availability
Person(s): Bunge, MarioType of Medium: UnknownPages: 374 S.ISBN: 3540039953Series Statement: Studies in the Foundations Methodology and Philosophy of ScienceLanguage: German -
3Printed BooksStaff View Availability
Person(s): Bunge, MarioType of Medium: UnknownPages: 217 S.Uniform Title: EpistemologiaLanguage: German -
4Printed BooksStaff View Availability
Person(s): Bunge, MarioType of Medium: UnknownPages: 250 S.Language: English -
5Printed BooksStaff View Availability
Person(s): Bunge, MarioType of Medium: UnknownPages: 263 S.Series Statement: Treatise on Basic PhilosophyLanguage: German -
6SSOARMinnen, Olivier van ; Linde, Maximilian ; Oude Lansink-Hartgring, Annemieke ; Boogaard, Bas van den ; Bunge, Jeroen J. H. ; Delnoij, Thijs S. R. ; Elzo Kraemer, Carlos V. ; Kuijpers, Marijn ; Maas, Jacinta J. ; Metz, Jesse de ; Poll, Marcel van de ; Reis Miranda, Dinis dos ; Vlaar, Alexander P. J. ; Ravenzwaaij, Don van ; Bergh, Walter M. van den
GBR
Published 2025Staff ViewPublication Date: 2025-07-04Description: Background: The RATE trial is a three-arm non-inferiority randomized controlled trial in adult patients treated with extracorporeal membrane oxygenation (ECMO) on the effect of anticoagulation levels on mortality, hemorrhagic, and thrombotic complications. The current protocol presents the rationale and analysis plan for evaluating the primary and secondary outcomes under the Bayesian framework. Methods: This protocol was drafted and submitted before study completion and, thus, the primary analysis. The primary outcome of the Bayesian analysis is mortality at 6 months. The secondary outcomes are severe hemorrhagic and thrombotic complications. We will use an uninformative prior for the primary analysis. Sensitivity analyses will be performed using a skeptical prior and an evidence-based informative prior. Conclusion: The proposed secondary, pre-planned Bayesian analysis of the RATE trial will provide additional information on the effect of different anticoagulation strategies during ECMO on complication rates. This additional Bayesian analysis will likely increase the validity of our results and complement the interpretation of the primary and several secondary outcomes. Trial registration: This trial is registered at https://clinicaltrials.gov/ (NCT04536272), registration date September 2, 2020. This trial is also registered at the Dutch trial register (NL7976).Keywords: Medizin und Gesundheit ; Medicine and health ; Medizin, Sozialmedizin ; Medicine, Social MedicineType: Zeitschriftenartikel, journal article -
7Articles: DFG German National LicensesWOOD, PATRICK ; MOYA, FERNANDO ; ELDRIDGE, CHARLES ; OWENS, GEOFFREY ; RANSCHT, BARBARA ; SCHACHNER, MELITTA ; BUNGE, MARY ; BUNGE, RICHARD
Oxford, UK : Blackwell Publishing Ltd
Published 1990Staff ViewISSN: 1749-6632Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: Natural Sciences in GeneralType of Medium: Electronic ResourceURL: -
8Articles: DFG German National LicensesBUNGE, MARY BARTLETT ; CLARK, MARY BLAIR ; DEAN, ANDY C. ; ELDRIDGE, CHARLES F. ; BUNGE, RICHARD P.
Oxford, UK : Blackwell Publishing Ltd
Published 1990Staff ViewISSN: 1749-6632Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: Natural Sciences in GeneralType of Medium: Electronic ResourceURL: -
9Articles: DFG German National LicensesMenei, Philippe ; Montero-Menei, Claudia ; Whittemore, Scott R. ; Bunge, Richard P. ; Bunge, Mary Bartlett
Oxford, UK : Blackwell Science, Ltd
Published 1998Staff ViewISSN: 1460-9568Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: The infusion of BDNF and NT-3 into Schwann cell (SC) grafts promotes regeneration of brainstem neurones into the grafts placed in adult rat spinal cord transected at T8 ( Xu et al. 1995b). Here, we compared normal SCs with SCs genetically modified to secrete human BDNF, grafted as trails 5 mm long in the cord distal to a transection site and also deposited in the transection site, for their ability to stimulate supraspinal axonal regeneration beyond the injury. SCs were infected with the replication-deficient retroviral vector pL(hBDNF)RNL encoding the human preproBDNF cDNA. The amounts of BDNF secreted (as detected by ELISA) were 23 and 5 ng/24 h per 106 cells for infected and normal SCs, respectively. Biological activity of the secreted BDNF was confirmed by retinal ganglion cell bioassay. The adult rat spinal cord was transected at T8. The use of Hoechst prelabelled SCs demonstrated that trails were maintained for a month. In controls, no SCs were grafted. One month after grafting, axons were present in SC trails. More 5-HT-positive and some DβH-positive fibres were observed in the infected vs. normal SC trails. When Fast Blue was injected 5 mm below the transection site (at the end of the trail), as many as 135 retrogradely labelled neurones could be found in the brainstem, mostly in the reticular and raphe nuclei (normal SCs, up to 22, mostly in vestibular nuclei). Numerous neurones were labelled in the ventral hypothalamus (normal SCs, 0). Also, following Fast Blue injection, a mean of 138 labelled cells was present in dorsal root ganglia (normal SCs, 46) and spinal cord (39 vs. 32) rostral to the transection. No labelled spinal neurones rostral to the transection were seen when SCs were not transplanted. Thus, the transplantation of SCs secreting increased amounts of BDNF improved the regenerative response across a transection site in the thoracic cord. Moreover, the enhanced regeneration observed with infected SCs may be specific as the largest response was from neurones known to express trkB.Type of Medium: Electronic ResourceURL: -
10Articles: DFG German National LicensesStaff View
ISSN: 0014-4827Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: BiologyMedicineType of Medium: Electronic ResourceURL: -
11Articles: DFG German National LicensesStaff View
ISSN: 0021-9991Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Computer SciencePhysicsType of Medium: Electronic ResourceURL: -
12Articles: DFG German National LicensesStaff View
ISSN: 0167-5087Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Energy, Environment Protection, Nuclear Power EngineeringPhysicsType of Medium: Electronic ResourceURL: -
13Articles: DFG German National LicensesStaff View
ISSN: 1749-6632Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: Natural Sciences in GeneralType of Medium: Electronic ResourceURL: -
14Articles: DFG German National LicensesStaff View
ISSN: 0097-8485Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Chemistry and PharmacologyType of Medium: Electronic ResourceURL: -
15Articles: DFG German National LicensesStaff View
ISSN: 0097-8485Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Chemistry and PharmacologyType of Medium: Electronic ResourceURL: -
16Articles: DFG German National LicensesStaff View
ISSN: 0097-8485Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Chemistry and PharmacologyType of Medium: Electronic ResourceURL: -
17Articles: DFG German National LicensesStaff View
ISSN: 0097-8485Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Chemistry and PharmacologyType of Medium: Electronic ResourceURL: -
18Articles: DFG German National LicensesStaff View
ISSN: 0097-8485Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Chemistry and PharmacologyType of Medium: Electronic ResourceURL: -
19Articles: DFG German National LicensesStaff View
ISSN: 0097-8485Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Chemistry and PharmacologyType of Medium: Electronic ResourceURL: -
20Articles: DFG German National LicensesStaff View
ISSN: 0097-8485Source: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: Chemistry and PharmacologyType of Medium: Electronic ResourceURL: